Oliver Luxxe Assets LLC Purchases 12,469 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Oliver Luxxe Assets LLC increased its stake in Halozyme Therapeutics by 44.9%, ending the first quarter with 40,239 shares worth approximately $2.57 million.
• CEO Helen Torley sold 20,000 shares for a total of $1.27 million, reducing her ownership to about 733,719 shares.
• Halozyme reported a significant quarterly earnings beat with an EPS of $1.54, surpassing analyst expectations by $0.31 and showing a revenue increase of 40.8% year-over-year.

Oliver Luxxe Assets LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 44.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 40,239 shares of the biopharmaceutical company's stock after buying an additional 12,469 shares during the quarter. Oliver Luxxe Assets LLC's holdings in Halozyme Therapeutics were worth $2,568,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. SVB Wealth LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $33,000. Bessemer Group Inc. lifted its holdings in Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 207 shares during the period. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Brooklyn Investment Group lifted its holdings in Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 670 shares during the period. Finally, Park Place Capital Corp lifted its holdings in Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after buying an additional 182 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on HALO. Wells Fargo & Company raised their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. HC Wainwright raised their target price on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price for the company. Finally, Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $67.11.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders sold 80,000 shares of company stock valued at $4,532,600. 2.90% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Up 0.3%

HALO stock traded up $0.25 on Wednesday, reaching $73.18. 3,208,595 shares of the company traded hands, compared to its average volume of 1,973,118. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $74.07. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company has a market cap of $8.56 billion, a P/E ratio of 16.75, a price-to-earnings-growth ratio of 0.41 and a beta of 1.17. The firm has a fifty day simple moving average of $59.88 and a 200-day simple moving average of $59.05.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm's revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter last year, the company earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.